Treatment
-
Going Off-LabelPhysicians are legally permitted to prescribe drugs approved for one purpose to be used for another, a practice called off-label prescribing. The rise of targeted therapies and immunotherapies is creating new challenges for navigating off-label options.
by Kate Yandell
-
A New Type of Drug ApprovalAt the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.
by Kate Yandell
-
Artificial Intelligence Characterizes CancerAt the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.
by Kevin McLaughlin
-
Non–Small Cell Lung Cancer Takes Center StageA trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non”“small cell lung cancer treatment.
by Brad Jones
-
Pembrolizumab Shows Further Promise for MelanomaIn a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
-
A Better Way to Screen for Lynch Syndrome?Researchers say a next-generation sequencing test could improve screening in colorectal cancer patients for a hereditary syndrome that raises cancer risk. Some experts have concerns.
by Cheryl Platzman Weinstock
-
-
Forward Look
Making Treatment DecisionsPersonal goals come into play for patients with advanced cancer.
by Kendall K. Morgan
-
Forward Look
Advances in Treating Non–Small Cell Lung CancerExpanded approvals in 2016 increase options.
by Jennifer L.W. Fink
-
Online Discussions Reveal Little-Known Side EffectsAnalyzing online patient conversations could shed light on adverse drug reactions.
by Brad Jones
